NASDAQ:ACAD - ACADIA Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$22.93 +0.67 (+3.01 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$22.93
Today's Range$22.13 - $22.96
52-Week Range$12.77 - $32.53
Volume1.41 million shs
Average Volume1.24 million shs
Market Capitalization$2.87 billion
P/E Ratio-9.72
Dividend YieldN/A
Beta3.32
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACAD
CUSIPN/A
Phone858-558-2871

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$124.90 million
Book Value$2.70 per share

Profitability

Net Income$-289,400,000.00
Net Margins-119.62%

Miscellaneous

Employees425
Market Cap$2.87 billion
Next Earnings Date2/26/2019 (Confirmed)
OptionableOptionable

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.45) by $0.06. The biopharmaceutical company earned $57.06 million during the quarter, compared to the consensus estimate of $58.63 million. ACADIA Pharmaceuticals had a negative net margin of 119.62% and a negative return on equity of 88.18%. The firm's revenue was up 87.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.55) EPS. View ACADIA Pharmaceuticals' Earnings History.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for ACADIA Pharmaceuticals.

How can I listen to ACADIA Pharmaceuticals' earnings call?

ACADIA Pharmaceuticals will be holding an earnings conference call on Tuesday, February 26th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8556384820.

What price target have analysts set for ACAD?

10 Wall Street analysts have issued 12-month target prices for ACADIA Pharmaceuticals' shares. Their predictions range from $17.00 to $60.00. On average, they anticipate ACADIA Pharmaceuticals' share price to reach $31.70 in the next twelve months. This suggests a possible upside of 38.2% from the stock's current price. View Analyst Price Targets for ACADIA Pharmaceuticals.

What is the consensus analysts' recommendation for ACADIA Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ACADIA Pharmaceuticals.

What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (1/31/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $30 price target on ACADIA. We recently hosted investors for a meeting with ACAD management on our Post ASH-Thrash Bus Tour. One focus of investor interest was the progress made by ACADIA on the NUPLAZID franchise since the removal of the safety concern overhang precipitated by what we view as an unfounded negative media article regarding the drug in PDP. Recall that in September 2018, the FDA announced that the label for NUPLAZID adequately characterized the known risks and that the agency still viewed benefits as outweighing risks for patients with PDP, especially in light of alternative off-label antipsych drugs." (12/5/2018)
  • 3. HC Wainwright analysts commented, "Our $60 PT is based on an equally weighted composite of: (a) $69/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $4.09 discounted back to and (b) an NPV of $50/share (discount rate 10%, growth rate 2.5%)." (11/1/2018)

Has ACADIA Pharmaceuticals been receiving favorable news coverage?

News stories about ACAD stock have been trending somewhat negative this week, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ACADIA Pharmaceuticals earned a news impact score of -1.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the next several days.

Who are some of ACADIA Pharmaceuticals' key competitors?

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Celgene (CELG), Micron Technology (MU), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Netflix (NFLX), Alibaba Group (BABA), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Citigroup (C).

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen R. Davis, CEO & Director (Age 58)
  • Dr. Srdjan R. Stankovic, Pres (Age 62)
  • Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 57)
  • Ms. Elena Ridloff C.F.A., CFA, Interim CFO & Sr. VP of Investor Relations
  • Mr. Eric Alejandro Miller, Controller & Principal Accounting Officer (Age 40)

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.10%), First Trust Advisors LP (3.31%), Great Point Partners LLC (2.20%), Northern Trust Corp (1.07%), Geode Capital Management LLC (1.00%) and Millennium Management LLC (0.72%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Glenn Baity and Laura Brege. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Which institutional investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Hudson Bay Capital Management LP, Emory University, Peregrine Capital Management LLC, Jane Street Group LLC, Fosun International Ltd, Weiss Multi Strategy Advisers LLC and Wealthstreet Investment Advisors LLC. View Insider Buying and Selling for ACADIA Pharmaceuticals.

Which institutional investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Millennium Management LLC, PNC Financial Services Group Inc., BlackRock Inc., Geode Capital Management LLC, D. E. Shaw & Co. Inc., Macquarie Group Ltd. and First Midwest Bank Trust Division. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Daniel B Soland. View Insider Buying and Selling for ACADIA Pharmaceuticals.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $22.93.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $2.87 billion and generates $124.90 million in revenue each year. The biopharmaceutical company earns $-289,400,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. ACADIA Pharmaceuticals employs 425 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is http://www.acadia-pharm.com.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]


MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  626 (Vote Outperform)
Underperform Votes:  325 (Vote Underperform)
Total Votes:  951
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel